全球免疫测量市场（按产品、技术、检体、应用、最终用户和地区划分）- 预测至 2030 年

预计 2025 年全球免疫测量市场价值将达到 355 亿美元，到 2030 年将达到 477 亿美元，预测期内复合年增长率为 6.1%。

推动这一增长的关键因素包括慢性病和感染疾病的增加、免疫测量係统的技术不断进步、政府的支持性政策以及由于严格的法规而对药物和酒精测试的重视程度的提高。

根据产品，全球免疫测量市场可细分为试剂和套件以及分析仪。试剂和套件是诊断市场中最重要的部分，主要是因为它们在各种诊断检测中经常使用。免疫测量方法的全球普及推动了对这些耗材的持续需求。此外，高性能试剂和套件的推出提高了诊断准确性和操作效率，也推动了其更广泛的应用，进一步推动了该领域的成长。

免疫测量市场按技术细分为酵素连结免疫测量(ELISA)、化学冷光免疫免疫萤光法(IFA)、快速检测、酵素连结免疫斑点法 (ELISpot)、西方墨点法和其他方法。预计化学化学冷光免疫测量测定 (CLIA) 领域将经历显着增长，主要原因是其具有适用于慢性病和感染疾病的先进诊断能力。与酵素连结免疫吸附试验 (ELISA) 和免疫测量等传统方法相比，CLIA 具有灵敏度高、动态范围广、週转时间快、背景干扰少和特异性高的特征。这些特点使 CLIA 成为首选，尤其是在需要高精度和高可靠性的临床诊断中。

全球免疫测量市场按应用细分为感染疾病、循环系统、内分泌疾病、肿瘤学、骨矿疾病、自体免疫疾病、血液筛检、过敏诊断、药物监测和检测、新生儿筛检等。 2022年，诊断检测市场受到感染疾病的严重影响，主要是由于爱滋病毒/爱滋病、肝炎、疟疾和流感等疾病的盛行率不断上升。免疫测量的使用在这一趋势中发挥关键作用，因为它们有助于快速准确的诊断，从而加强全球感染疾病疫情的管理。

免疫测量市场按地区细分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。预计亚太地区将在预测期内实现最高成长。这种快速扩张可归因于几个相互关联的因素，即患者人数的显着增长、慢性病患病率的上升、人们对早期疾病检测重要性的认识不断提高，以及中国、医疗保健系统和东南亚国家医疗基础设施的持续加强。

本报告研究了全球免疫测量市场，并提供了按产品、技术、检体、应用、最终用户和地区分類的趋势信息，以及参与市场的公司概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章市场概述

• 介绍
• 市场动态
• 监管分析
• 技术分析
• 贸易分析
• 专利分析
• 价值链分析
• 供应链分析
• 生态系分析
• 波特五力分析
• 主要相关人员和采购标准
• 2025-2026年主要会议和活动
• 定价分析
• 影响客户业务的趋势/中断
• 案例研究分析
• 投资金筹措场景
• 人工智慧/生成式人工智慧对免疫测量市场的影响
• 2025年美国关税对免疫测量市场的影响

第六章免疫测量市场（按产品）

• 介绍
• 试剂和套件
• 分析仪

第七章免疫测量市场（按技术）

• 介绍
• ELISA
• CLIA
• IFA
• 快速检测
• 西方印渍术
• ELISpot
• 其他的

第八章免疫测量市场（按检体）

• 介绍
• 血
• 唾液
• 尿
• 其他的

第九章免疫测量市场（按应用）

• 介绍
• 感染疾病
• 内分泌学
• 心臟病学
• 自体免疫疾病
• 过敏诊断
• 肿瘤学
• 骨骼和矿物质疾病
• 药物监测与检测
• 血液检查
• 新生儿筛检
• 其他的

第 10 章。免疫测量市场（按最终用户）

• 介绍
• 医院和诊所
• 临床实验室
• 居家照护
• 血库

第 11 章免疫测量市场（按地区）

• 介绍
• 北美洲
  • 北美宏观经济展望
  • 美国
  • 加拿大
• 欧洲
  • 欧洲宏观经济展望
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 英国
  • 俄罗斯
  • 其他的
• 亚太地区
  • 亚太宏观经济展望
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 印尼
  • 其他的
• 拉丁美洲
  • 拉丁美洲宏观经济展望
  • 巴西
  • 墨西哥
  • 其他的
• 中东和非洲
  • 熟练实验室人员的短缺和不利的报销政策限制了市场的成长

第十二章竞争格局

• 介绍
• 主要参与企业的策略/优势
• 2020-2024年收益分析
• 2024年市场占有率分析
• 公司估值矩阵：2024 年关键参与企业
• 公司估值矩阵：Start-Ups/中小企业，2024 年
• 估值和财务指标
• 品牌/产品比较
• 竞争场景

第十三章：公司简介

• 主要参与企业
  • ABBOTT
  • F. HOFFMANN-LA ROCHE LTD.
  • SIEMENS HEALTHINEERS AG
  • DANAHER
  • THERMO FISHER SCIENTIFIC INC.
  • REVVITY
  • BECTON, DICKINSON AND COMPANY（BD）
  • DIASORIN SPA
  • BIO-RAD LABORATORIES, INC.
  • QUIDELORTHO CORPORATION
  • BIOMERIEUX
  • QIAGEN
  • SYSMEX CORPORATION
  • AGILENT TECHNOLOGIES, INC.
  • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
• 其他公司
  • MERCK KGAA
  • MERIDIAN BIOSCIENCE
  • BIO-TECHNE
  • CELLABS
  • ABNOVA CORPORATION
  • J. MITRA & CO. PVT. LTD.
  • TOSOH CORPORATION（TOSOH BIOSCIENCES）
  • CELL SCIENCES
  • ENZO BIOCHEM INC.
  • CREATIVE DIAGNOSTICS
  • BOSTER BIOLOGICAL TECHNOLOGY
  • ELABSCIENCE BIONOVATON INC.
  • WAK-CHEMIE MEDICAL GMBH
  • SERA CARE
  • EPITOPE DIAGNOSTICS, INC.
  • KAMIYA BIOMEDICAL COMPANY
  • GYROS PROTEIN TECHNOLOGIES AB
  • TRIVITRON HEALTHCARE
  • INBIOS INTERNATIONAL, INC.
  • MACCURA BIOTECHNOLOGY CO., LTD.

第十四章 附录

The global immunoassay market is valued at an estimated USD 35.5 billion in 2025 and is projected to reach USD 47.7 billion by 2030, at a CAGR of 6.1% during the forecast period. Key factors driving this growth include the increasing rates of chronic and infectious diseases, continuous technological progress in immunoassay systems, supportive government policies, and a growing emphasis on drug and alcohol testing due to strict regulations.

"The reagents & kits accounted for the largest share of the immunoassay products market."

On the basis of products, the global immunoassay market is segmented into reagents & kits and analyzers. Reagents & kits represent the most substantial segment in the diagnostic market, primarily due to their frequent application in a wide array of diagnostic assays. The ongoing demand for these consumables is fueled by the increasing global incidence of immunoassay procedures. Furthermore, the introduction of high-performance reagents and kits, which enhance diagnostic precision and operational efficiency, has facilitated their broader adoption and subsequently spurred growth within this sector.

"The chemiluminescence Immunoassay (CLIA) segment is projected to grow at a considerable rate in the immunoassay technology segment during the forecast period."

The immunoassay market is categorized by technology into ELISA, chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other methods. The CLIA (Chemiluminescent Immunoassays) segment is forecasted to experience substantial growth, largely due to its advanced diagnostic capabilities applicable to both chronic and infectious diseases. When contrasted with conventional methods like ELISA (Enzyme-Linked Immunosorbent Assay) and radioimmunoassays, CLIA demonstrates superior sensitivity, an extended dynamic range, expedited turnaround times, minimized background interference, and enhanced specificity. These attributes make CLIA the preferred choice for clinical diagnostics, particularly in situations demanding high accuracy and reliability.

"Infectious diseases held the largest share of the immunoassay applications market."

The global immunoassay market is categorized by application into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring & testing, newborn screening, and other applicatons. In 2022, the market for diagnostic testing was predominantly influenced by infectious diseases, largely due to the increasing incidence of conditions like HIV/AIDS, hepatitis, malaria, and influenza. The utilization of immunoassays has played a critical role in this trend, as these tests facilitate rapid and precise diagnoses, thereby enhancing the management of global infectious disease outbreaks.

"Asia Pacific is expected to be the fastest-growing region in the immunoassay market."

The immunoassay market is regionally segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is anticipated to experience the most significant growth during the forecast period. This rapid expansion can be attributed to several interrelated factors: a substantial and expanding patient demographic, an escalating prevalence of chronic diseases, heightened awareness of the importance of early disease detection, and continuous enhancements in healthcare infrastructure in nations such as China, India, and various Southeast Asian countries.

The break-up of the profile of primary participants in the immunoassay market:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: CXOs and Directors- 30%, Managers- 45%, and Executives- 25%
• By Region: North America -35%, Europe - 25%, Asia Pacific -15%, Latin America -10%, Middle East- 10%, and Africa- 5%

The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher (US), Thermo Fisher Scientific Inc. (US), Revvity (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMerieux (France), QIAGEN (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (India), and Maccura Biotechnology Co., Ltd. (China).

Research Coverage:

This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen (blood, urine, saliva, and other specimens), technology (ELISA, CLIA, IFA, rapid tests, ELISpot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone & mineral disorders, autoimmune disorders, cardiology, drug monitoring & testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals & clinics, blood banks, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors such as drivers, restraints, opportunities, and challenges influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, as well as recent developments associated with the immunoassay market, are also included. This report covers the competitive landscape of upcoming startups in the immunoassay market ecosystem.

Key Benefits of Buying the Report:

The report provides market leaders and new entrants with estimates of revenue figures for the overall immunoassay market and its subsegments. It helps stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, growth in biotechnology and biopharmaceutical industries, supportive government policies, increasing adoption of immunoassay-based poc testing and rapid testing, increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (stringent requirements for approval of immunoassay instruments and consumables, technical hurdles of immunoassay kits), opportunities (growth opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavorable reimbursement scenario, influencing the growth of the immunoassay market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the immunoassay market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher (US), and Bio-Rad Laboratories, Inc. (US), among others, in the immunoassay market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IMMUNOASSAY MARKET OVERVIEW
• 4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY
• 4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT
• 4.4 IMMUNOASSAY MARKET: REGIONAL MIX

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of chronic and infectious diseases
      • 5.2.1.1.1 Increased use of immunoassays in oncology
      • 5.2.1.1.2 Rising use of immunoassays in diagnostic applications
      • 5.2.1.1.3 High geriatric population
    • 5.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures
    • 5.2.1.3 Growth in biotechnology & biopharmaceutical industries
    • 5.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing
    • 5.2.1.5 Supportive government regulatory policies and initiatives
    • 5.2.1.6 Increased consumption of drugs, alcohol, and cannabis
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables
    • 5.2.2.2 Technical hurdles of immunoassay kits
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing growth opportunities in emerging economies
    • 5.2.3.2 Focus on importance of companion diagnostics
    • 5.2.3.3 Development of condition-specific biomarkers and tests
    • 5.2.3.4 Integration of microfluidics in immunoassays
    • 5.2.3.5 Improving immunoassay diagnostic technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Design challenges and low quality of antibodies
    • 5.2.4.2 Dearth of skilled professionals
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY FRAMEWORK
    • 5.3.1.1 North America
      • 5.3.1.1.1 US
      • 5.3.1.1.2 Canada
    • 5.3.1.2 Europe
      • 5.3.1.2.1 Russia
    • 5.3.1.3 Asia Pacific
      • 5.3.1.3.1 Japan
      • 5.3.1.3.2 China
      • 5.3.1.3.3 India
      • 5.3.1.3.4 Indonesia
      • 5.3.1.3.5 South Korea
    • 5.3.1.4 Middle East
      • 5.3.1.4.1 Saudi Arabia
    • 5.3.1.5 Latin America
      • 5.3.1.5.1 Mexico
      • 5.3.1.5.2 Brazil
    • 5.3.1.6 Africa
  • 5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 ELISA
  • 5.4.2 ADJACENT TECHNOLOGIES
    • 5.4.2.1 Microfluidics and miniaturized platforms
  • 5.4.3 COMPLEMENTARY TECHNOLOGIES
    • 5.4.3.1 Lateral flow assays
• 5.5 TRADE ANALYSIS
  • 5.5.1 IMPORT DATA FOR HS CODE 382200, 2019-2024
  • 5.5.2 EXPORT DATA FOR HS CODE 382200, 2019-2024
• 5.6 PATENT ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 SUPPLY CHAIN ANALYSIS
• 5.9 ECOSYSTEM ANALYSIS
  • 5.9.1 ROLE IN ECOSYSTEM
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF SUPPLIERS
  • 5.10.3 BARGAINING POWER OF BUYERS
  • 5.10.4 THREAT OF SUBSTITUTES
  • 5.10.5 THREAT OF NEW ENTRANTS
• 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 KEY BUYING CRITERIA
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.13.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANAYZERS, BY REGION, 2022-2024
  • 5.13.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022-2024
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING
  • 5.15.2 MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION
  • 5.15.3 LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET
  • 5.17.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS
  • 5.17.2 FUTURE OF AI/GEN AI IN IMMUNOASSAY MARKET
• 5.18 IMPACT OF 2025 US TARIFF ON IMMUNOASSAY MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
      • 5.18.4.1.1 US
    • 5.18.4.2 Europe
      • 5.18.4.2.1 Germany
      • 5.18.4.2.2 UK and France
    • 5.18.4.3 Asia Pacific
      • 5.18.4.3.1 China
      • 5.18.4.3.2 Japan
      • 5.18.4.3.3 India
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & clinics
    • 5.18.5.2 Clinical laboratories
    • 5.18.5.3 Blood banks
    • 5.18.5.4 Home care settings

6 IMMUNOASSAY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 REAGENTS & KITS
  • 6.2.1 ELISA REAGENTS & KITS
    • 6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
  • 6.2.2 RAPID TEST REAGENTS & KITS
    • 6.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth
  • 6.2.3 ELISPOT REAGENTS & KITS
    • 6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to aid segment growth
  • 6.2.4 CLIA REAGENTS & KITS
    • 6.2.4.1 Better diagnosis and higher specificity to augment segment growth
  • 6.2.5 IFA REAGENTS & KITS
    • 6.2.5.1 Better adaptability in clinical diagnostics to support segment growth
  • 6.2.6 WESTERN BLOT REAGENTS & KITS
    • 6.2.6.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation
  • 6.2.7 OTHER REAGENTS & KITS
• 6.3 ANALYZERS
  • 6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE
    • 6.3.1.1 Open-ended systems
      • 6.3.1.1.1 Better flexibility and wider availability to drive segment growth
    • 6.3.1.2 Closed-ended systems
      • 6.3.1.2.1 Higher precision and better automation to fuel segment growth
  • 6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
    • 6.3.2.1 Rental purchase
      • 6.3.2.1.1 Increased convenience and reduced liability to boost segment growth
    • 6.3.2.2 Outright purchase
      • 6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth

7 IMMUNOASSAY MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 ELISA
  • 7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
• 7.3 CLIA
  • 7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH
• 7.4 IFA
  • 7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
• 7.5 RAPID TESTS
  • 7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS
• 7.6 WESTERN BLOTTING
  • 7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH
• 7.7 ELISPOT
  • 7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO PROPEL MARKET GROWTH
• 7.8 OTHER TECHNOLOGIES

8 IMMUNOASSAY MARKET, BY SPECIMEN

• 8.1 INTRODUCTION
• 8.2 BLOOD
  • 8.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH
• 8.3 SALIVA
  • 8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH
• 8.4 URINE
  • 8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH
• 8.5 OTHER SPECIMENS

9 IMMUNOASSAY MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 INFECTIOUS DISEASES
  • 9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
• 9.3 ENDOCRINOLOGY
  • 9.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH
• 9.4 CARDIOLOGY
  • 9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH
• 9.5 AUTOIMMUNE DISORDERS
  • 9.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH
• 9.6 ALLERGY DIAGNOSTICS
  • 9.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH
• 9.7 ONCOLOGY
  • 9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH
• 9.8 BONE & MINERAL DISORDERS
  • 9.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH
• 9.9 DRUG MONITORING & TESTING
  • 9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH
• 9.10 BLOOD SCREENING
  • 9.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH
• 9.11 NEWBORN SCREENING
  • 9.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH
• 9.12 OTHER APPLICATIONS

10 IMMUNOASSAY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUME TO DRIVE MARKET
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
• 10.4 HOME CARE SETTINGS
  • 10.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH
• 10.5 BLOOD BANKS
  • 10.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH

11 IMMUNOASSAY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate North American immunoassay market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing government support and rising incidence of chronic diseases to augment market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High healthcare spending and favorable government initiatives to propel market growth
  • 11.3.3 ITALY
    • 11.3.3.1 Rising geriatric population and increasing cancer prevalence to spur market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Increased use of POC testing and favorable reimbursement policies to boost market growth
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth
  • 11.3.6 UK
    • 11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market
  • 11.3.7 RUSSIA
    • 11.3.7.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth
  • 11.4.3 CHINA
    • 11.4.3.1 Increasing government investments and rising geriatric population to accelerate maket growth
  • 11.4.4 INDIA
    • 11.4.4.1 Growing medical tourism and improving healthcare infrastructure to propel market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising healthcare spending and increasing research investments to fuel market growth
  • 11.4.7 INDONESIA
    • 11.4.7.1 High geriatric population and favorable government healthcare policies to accelerate market growth
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 High incidence of infectious diseases and presence of academic & research institutes to boost market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Specimen footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 List of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES/APPROVALS/ ENHANCEMENTS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ABBOTT
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 SIEMENS HEALTHINEERS AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches and approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 DANAHER
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches and approvals
      • 13.1.4.3.2 Deals
      • 13.1.4.3.3 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 THERMO FISHER SCIENTIFIC INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 REVVITY
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
      • 13.1.6.3.2 Other developments
  • 13.1.7 BECTON, DICKINSON AND COMPANY (BD)
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Expansions
  • 13.1.8 DIASORIN S.P.A.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches and approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 BIO-RAD LABORATORIES, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
      • 13.1.9.3.2 Deals
  • 13.1.10 QUIDELORTHO CORPORATION
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product approvals
      • 13.1.10.3.2 Deals
      • 13.1.10.3.3 Expansions
  • 13.1.11 BIOMERIEUX
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches and approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 QIAGEN
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 SYSMEX CORPORATION
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
      • 13.1.13.3.2 Expansions
  • 13.1.14 AGILENT TECHNOLOGIES, INC.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches and approvals
      • 13.1.14.3.2 Deals
      • 13.1.14.3.3 Other developments
  • 13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 MERCK KGAA
  • 13.2.2 MERIDIAN BIOSCIENCE
  • 13.2.3 BIO-TECHNE
  • 13.2.4 CELLABS
  • 13.2.5 ABNOVA CORPORATION
  • 13.2.6 J. MITRA & CO. PVT. LTD.
  • 13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES)
  • 13.2.8 CELL SCIENCES
  • 13.2.9 ENZO BIOCHEM INC.
  • 13.2.10 CREATIVE DIAGNOSTICS
  • 13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
  • 13.2.12 ELABSCIENCE BIONOVATON INC.
  • 13.2.13 WAK-CHEMIE MEDICAL GMBH
  • 13.2.14 SERA CARE
  • 13.2.15 EPITOPE DIAGNOSTICS, INC.
  • 13.2.16 KAMIYA BIOMEDICAL COMPANY
  • 13.2.17 GYROS PROTEIN TECHNOLOGIES AB
  • 13.2.18 TRIVITRON HEALTHCARE
  • 13.2.19 INBIOS INTERNATIONAL, INC.
  • 13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS

List of Tables

• TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
• TABLE 3 IMMUNOASSAY MARKET: MARKET ASSUMPTIONS
• TABLE 4 IMMUNOASSAY MARKET: RISK ANALYSIS
• TABLE 5 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
• TABLE 6 PROJECTED NUMBER OF CANCER PATIENTS, BY CANCER TYPE, 2015 VS. 2018 VS. 2035 (UNITS)
• TABLE 7 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING
• TABLE 8 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
• TABLE 9 RECENT DEVELOPMENTS IN IMMUNOASSAY MARKET, 2021-2023
• TABLE 10 NEW TESTS LAUNCHED BY KEY PLAYERS, 2021-2023
• TABLE 11 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS
• TABLE 12 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS
• TABLE 13 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES
• TABLE 14 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES
• TABLE 15 JAPAN: CLASSIFICATION OF IN-VIRTO DIAGNOSTIC REAGENTS
• TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 17 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 18 INDONESIA: REGISTRATION PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 20 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 21 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 27 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
• TABLE 28 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
• TABLE 29 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION)
• TABLE 30 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION)
• TABLE 31 IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM
• TABLE 32 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES
• TABLE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
• TABLE 34 KEY BUYING CRITERIA, BY END USER
• TABLE 35 IMMUNOASSAY MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 36 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
• TABLE 37 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS, BY REGION, 2022-2024 (USD)
• TABLE 38 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022-2024 (USD)
• TABLE 39 CASE STUDY 1: PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING
• TABLE 40 CASE STUDY 2: MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION
• TABLE 41 CASE STUDY 3: LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING
• TABLE 42 US ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET
• TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 62 NORTH AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 EUROPE: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 ASIA PACIFIC: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 LATIN AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 CLIA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 67 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 69 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 70 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 IFA REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 72 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 75 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 77 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 81 OTHER REAGENTS & KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 82 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 83 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 84 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 KEY ANALYZERS AVAILABLE IN MARKET
• TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 88 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 90 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 91 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 92 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 93 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 94 NORTH AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 EUROPE: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 ASIA PACIFIC: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 97 LATIN AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 99 NORTH AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 EUROPE: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 ASIA PACIFIC: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 LATIN AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 103 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 104 RENTAL PURCHASE MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 105 NORTH AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 EUROPE: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 ASIA PACIFIC: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 LATIN AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 OUTRIGHT PURCHASE MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 110 NORTH AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 111 EUROPE: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 ASIA PACIFIC: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 113 LATIN AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 115 IMMUNOASSAY TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 116 NORTH AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 117 EUROPE: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 118 ASIA PACIFIC: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 119 LATIN AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 120 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET
• TABLE 121 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 126 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 127 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 129 ASIA PACIFIC: IMMUNOASSAY MARKET CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 130 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 131 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 132 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 133 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 ASIA PACIFIC: IMMUNOASSAY MARKET IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 135 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 136 KEY RAPID TESTS AVAILABLE IN MARKET
• TABLE 137 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 138 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 139 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 140 ASIA PACIFIC: IMMUNOASSAY MARKET RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 141 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 142 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
• TABLE 143 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 144 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 145 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 146 ASIA PACIFIC: IMMUNOASSAY MARKET WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 147 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 148 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 149 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 150 EUROPE: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 151 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 152 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 153 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 154 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 155 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 156 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 157 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 158 IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 159 IMMUNOASSAY SPECIMEN MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 160 NORTH AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 161 EUROPE: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 162 ASIA PACIFIC: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 163 LATIN AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 164 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2023-2030 (USD MILLION)
• TABLE 165 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 166 EUROPE: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 167 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 168 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 169 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 170 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 171 EUROPE: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 172 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 173 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 174 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2023-2030 (USD MILLION)
• TABLE 175 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 176 EUROPE: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 177 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 178 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 179 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 180 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 181 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 183 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 184 IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 185 IMMUNOASSAY APPLICATION MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 186 NORTH AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 187 EUROPE: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 188 ASIA PACIFIC: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 189 LATIN AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 190 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 191 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 192 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 194 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 195 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 196 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 197 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 199 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 200 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS
• TABLE 201 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 202 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 203 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 204 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 205 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 206 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 207 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 208 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 209 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 210 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 211 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 212 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 213 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 215 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 216 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
• TABLE 217 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 218 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 219 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 220 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 221 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 222 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS
• TABLE 223 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 224 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 225 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 226 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 227 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 228 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
• TABLE 229 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
• TABLE 230 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 231 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 232 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 233 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 234 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 235 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 236 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 237 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 238 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 239 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 240 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING
• TABLE 241 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 246 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 248 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 249 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 251 IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 252 IMMUNOASSAY END USER MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 253 NORTH AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 254 EUROPE: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 255 ASIA PACIFIC: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 256 LATIN AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 257 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 258 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 259 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 260 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 261 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 262 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 263 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 264 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 265 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 266 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 267 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 268 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 269 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 270 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 271 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 272 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 273 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 274 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 275 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 277 IMMUNOASSAY MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 278 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 279 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 280 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 281 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 282 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 283 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 284 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 285 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 286 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 287 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 288 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022-2030 (BILLION UNITS)
• TABLE 289 US: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 290 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 291 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 292 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 293 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 294 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 295 US: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 296 US: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 297 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034
• TABLE 298 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 299 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 300 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 301 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 302 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 303 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 304 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 305 CANADA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 306 EUROPE: KEY MACROINDICATORS
• TABLE 307 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 308 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 309 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 310 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 311 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 312 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 313 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 314 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 315 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 316 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 317 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 318 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 319 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 320 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 321 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 322 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 323 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 324 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 325 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 326 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 327 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 328 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 329 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 330 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 331 ITALY: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 332 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 333 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 334 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 335 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 336 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 337 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 338 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 339 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 340 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 341 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 342 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 343 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 344 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 345 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 346 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 347 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 348 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 349 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 350 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 351 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 352 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 353 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 354 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 355 UK: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 356 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 357 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 358 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 359 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 360 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 361 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 362 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 363 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 364 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 365 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 366 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 367 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 368 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 369 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 370 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 371 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 372 ASIA PACIFIC: KEY MACROINDICATORS
• TABLE 373 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 374 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 375 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 376 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 377 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 378 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 379 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 380 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 381 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 382 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 383 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 384 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 385 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 386 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 387 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 388 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 389 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 390 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 391 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 392 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 393 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 394 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 395 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 396 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 397 CHINA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 398 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 399 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 400 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 401 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 402 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 403 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 404 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 405 INDIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 406 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 407 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 408 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 409 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 410 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 411 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 412 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 413 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 414 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 415 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 416 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 417 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 418 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 419 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 420 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 421 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 422 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 423 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 424 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 425 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 426 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 427 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 428 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 429 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 430 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 431 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 432 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 433 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 434 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 435 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 436 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 437 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 438 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 439 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 440 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 441 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 442 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 443 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 444 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 445 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 446 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 447 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 448 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 449 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 450 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 451 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 452 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 453 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 454 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 455 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 456 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 457 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 458 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 459 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 460 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 461 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 462 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 463 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 464 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 465 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 466 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 467 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 468 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 469 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 470 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 471 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 472 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 473 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 474 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 475 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023-2030 (USD MILLION)
• TABLE 476 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 477 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023-2030 (USD MILLION)
• TABLE 478 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 479 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 480 OVERVIEW OF KEY STRATEGIES DEPLOYED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET
• TABLE 481 IMMUNOASSAY MARKET: DEGREE OF COMPETITION
• TABLE 482 IMMUNOASSAY MARKET: REGION FOOTPRINT
• TABLE 483 IMMUNOASSAY MARKET: PRODUCT FOOTPRINT
• TABLE 484 IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT
• TABLE 485 IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS
• TABLE 486 IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY REGION
• TABLE 487 IMMUNOASSAY MARKET: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022-JULY 2025
• TABLE 488 IMMUNOASSAY MARKET: DEALS, JANUARY 2022-JULY 2025
• TABLE 489 ABBOTT: COMPANY OVERVIEW
• TABLE 490 ABBOTT: PRODUCTS OFFERED
• TABLE 491 ABBOTT: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 492 ABBOTT: DEALS, JANUARY 2022-JUNE 2025
• TABLE 493 ABBOTT: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 494 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 495 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 496 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 497 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 498 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 499 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 500 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
• TABLE 501 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 502 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022-JUNE 2025
• TABLE 503 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 504 DANAHER: COMPANY OVERVIEW
• TABLE 505 DANAHER: PRODUCTS OFFERED
• TABLE 506 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 507 DANAHER: DEALS, JANUARY 2022-JUNE 2025
• TABLE 508 DANAHER: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 509 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 510 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
• TABLE 511 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 512 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 513 REVVITY: COMPANY OVERVIEW
• TABLE 514 REVVITY: PRODUCTS OFFERED
• TABLE 515 REVVITY: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 516 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 517 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
• TABLE 518 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
• TABLE 519 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 520 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 521 DIASORIN S.P.A.: PRODUCTS OFFERED
• TABLE 522 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 523 DIASORIN S.P.A.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 524 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 525 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
• TABLE 526 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
• TABLE 527 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• TABLE 529 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
• TABLE 530 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 531 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022-JUNE 2025
• TABLE 532 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 533 BIOMERIEUX: COMPANY OVERVIEW
• TABLE 534 BIOMERIEUX: PRODUCTS OFFERED
• TABLE 535 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 536 BIOMERIEUX: DEALS, JANUARY 2022-JUNE 2025
• TABLE 537 QIAGEN: COMPANY OVERVIEW
• TABLE 538 QIAGEN: PRODUCTS OFFERED
• TABLE 539 QIAGEN: DEALS, JANUARY 2022-JUNE 2025
• TABLE 540 SYSMEX CORPORATION: COMPANY OVERVIEW
• TABLE 541 SYSMEX CORPORATION: PRODUCTS OFFERED
• TABLE 542 SYSMEX CORPORATION: DEALS, JANUARY 2022-JUNE 2025
• TABLE 543 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022-JUNE 2025
• TABLE 544 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 545 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
• TABLE 546 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2025
• TABLE 547 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-JUNE 2025
• TABLE 548 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
• TABLE 549 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
• TABLE 550 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
• TABLE 551 MERCK KGAA: COMPANY OVERVIEW
• TABLE 552 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW
• TABLE 553 BIO-TECHNE: COMPANY OVERVIEW
• TABLE 554 CELLABS: COMPANY OVERVIEW
• TABLE 555 ABNOVA CORPORATION: COMPANY OVERVIEW
• TABLE 556 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
• TABLE 557 TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW
• TABLE 558 CELL SCIENCES: COMPANY OVERVIEW
• TABLE 559 ENZO BIOCHEM INC.: COMPANY OVERVIEW
• TABLE 560 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 561 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
• TABLE 562 ELABSCIENCE BIONOVATON INC.: COMPANY OVERVIEW
• TABLE 563 WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW
• TABLE 564 SERA CARE: COMPANY OVERVIEW
• TABLE 565 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 566 KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW
• TABLE 567 GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW
• TABLE 568 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
• TABLE 569 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
• TABLE 570 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED
• FIGURE 3 IMMUNOASSAY MARKET: RESEARCH DESIGN
• FIGURE 4 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES
• FIGURE 5 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES
• FIGURE 6 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
• FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
• FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 9 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION (REVENUE SHARE ANALYSIS)
• FIGURE 10 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS)
• FIGURE 11 IMMUNOASSAY MARKET: TOP-DOWN APPROACH
• FIGURE 12 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY
• FIGURE 13 IMMUNOASSAY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
• FIGURE 14 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD BILLION)
• FIGURE 15 IMMUNOASSAY MARKET, BY SPECIMEN, 2025 VS. 2030 (USD BILLION)
• FIGURE 16 IMMUNOASSAY MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION)
• FIGURE 17 IMMUNOASSAY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
• FIGURE 18 REGIONAL SNAPSHOT OF IMMUNOASSAY MARKET
• FIGURE 19 FAVORABLE REGULATORY SCENARIO AND HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
• FIGURE 20 US AND REAGENTS & KITS COMMANDED LARGEST SHARE OF NORTH AMERICAN IMMUNOASSAY MARKET IN 2024
• FIGURE 21 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 22 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
• FIGURE 23 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 24 RATE OF INCREASE IN INCIDENCE OF DIABETES GLOBALLY (IN MILLION)
• FIGURE 25 US: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 26 CANADA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 28 INDIA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
• FIGURE 31 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET, JANUARY 2015-DECEMBER 2024
• FIGURE 32 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS
• FIGURE 33 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 34 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS
• FIGURE 35 IMMUNOASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
• FIGURE 37 KEY BUYING CRITERIA FOR TOP END USERS
• FIGURE 38 IMMUNOASSAY MARKET: TRENDS/DISTRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 39 IMMUNOASSAY MARKET: FUNDING AND NUMBER OF DEALS, 2018-2025 (USD MILLION)
• FIGURE 40 MARKET POTENTIAL OF AI/GEN AI IN ENHANCING IMMUNOASSAY DIAGNOSIS AND TREATMENT PLANNING
• FIGURE 41 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
• FIGURE 42 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
• FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2020-2024)
• FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2024)
• FIGURE 45 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 46 IMMUNOASSAY MARKET: COMPANY FOOTPRINT
• FIGURE 47 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 48 EV/EBITDA OF KEY VENDORS, 2025
• FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
• FIGURE 50 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 51 ABBOTT: COMPANY SNAPSHOT
• FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
• FIGURE 54 DANAHER: COMPANY SNAPSHOT
• FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
• FIGURE 56 REVVITY: COMPANY SNAPSHOT
• FIGURE 57 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
• FIGURE 58 DIASORIN S.P.A.: COMPANY SNAPSHOT
• FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
• FIGURE 60 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT
• FIGURE 61 BIOMERIEUX: COMPANY SNAPSHOT
• FIGURE 62 QIAGEN: COMPANY SNAPSHOT
• FIGURE 63 SYSMEX CORPORATION: COMPANY SNAPSHOT
• FIGURE 64 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
• FIGURE 65 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT